Prils Market Share

  • Report ID: 4109
  • Published Date: Nov 21, 2025
  • Report Format: PDF, PPT

Prils Market - Regional Analysis

North American Market Forecast

The prils market in North America is projected to be the largest with a share of about 41% by the end of 2035. The growth of the market can be attributed majorly to the increasing cases of obesity. For instance, the chance of developing hypertension and other cardiovascular disorders increases with obesity, which could result in a rise in the demand for hypertension drugs.

Further, the growing healthcare infrastructure in the region, along with the high prevalence of neurological disorders, is also anticipated to contribute to the market growth in the region. According to estimates, between 2017 and 2020, more than 40% of US people were obese, making it one of the most prevalent health issues in the country.

European Market Statistics

Europe industry is predicted to account for largest revenue share of 31% by 2035. The growth of the market can be attributed majorly to the increasing initiatives to assist the expansion of generic medications through pricing and reimbursement. Generic prils may be used more frequently as a result, which could raise demand for these drugs.

In addition, the region's favorable government policies and surging expenditure on research and development activities are also anticipated to boost market growth during the forecast period.

Prils Market size

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of prils is evaluated at USD 2.65 billion.

The global prils market size was worth more than USD 2.51 billion in 2025 and is poised to witness a CAGR of over 6.4%, crossing USD 4.67 billion revenue by 2035.

North America is anticipated to command a 41% share of the Prils Market by 2035, owing to the increasing cases of obesity.

Key players in the market include Teva Pharmaceuticals Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Pfizer Inc., Mylan N.V, F. Hoffmann-La Roche Ltd., Novartis AG, Manus Aktteva Biopharma LLP, Canagen Pharmaceuticals Inc., Lupin Limited.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos